Changes in the plasma proteome at asymptomatic and symptomatic stages of autosomal dominant Alzheimer’s disease

被引:0
|
作者
Julia Muenchhoff
Anne Poljak
Anbupalam Thalamuthu
Veer B. Gupta
Pratishtha Chatterjee
Mark Raftery
Colin L. Masters
John C. Morris
Randall J. Bateman
Anne M. Fagan
Ralph N. Martins
Perminder S. Sachdev
机构
[1] Centre for Healthy Brain Ageing,Department of Neurology
[2] School of Psychiatry,Department of Pathology and Immunology
[3] University of New South Wales,undefined
[4] Bioanalytical Mass Spectrometry Facility,undefined
[5] University of New South Wales,undefined
[6] School of Medical Sciences,undefined
[7] University of New South Wales,undefined
[8] Centre of Excellence for Alzheimer’s disease Research & Care,undefined
[9] School of Medical Sciences,undefined
[10] Edith Cowan University,undefined
[11] Sir James McCusker Alzheimer’s Disease Research Unit (Hollywood Private Hospital),undefined
[12] School of Psychiatry and Clinical Neurosciences,undefined
[13] University of Western Australia,undefined
[14] University of Melbourne,undefined
[15] Washington University School of Medicine,undefined
[16] Knight Alzheimer’s Disease Research Center at Washington University School of Medicine,undefined
[17] Washington University School of Medicine,undefined
[18] Neuropsychiatric Institute,undefined
[19] Prince of Wales Hospital,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The autosomal dominant form of Alzheimer’s disease (ADAD) is far less prevalent than late onset Alzheimer’s disease (LOAD), but enables well-informed prospective studies, since symptom onset is near certain and age of onset is predictable. Our aim was to discover plasma proteins associated with early AD pathology by investigating plasma protein changes at the asymptomatic and symptomatic stages of ADAD. Eighty-one proteins were compared across asymptomatic mutation carriers (aMC, n = 15), symptomatic mutation carriers (sMC, n = 8) and related noncarriers (NC, n = 12). Proteins were also tested for associations with cognitive measures, brain amyloid deposition and glucose metabolism. Fewer changes were observed at the asymptomatic than symptomatic stage with seven and 16 proteins altered significantly in aMC and sMC, respectively. This included complement components C3, C5, C6, apolipoproteins A-I, A-IV, C-I and M, histidine-rich glycoprotein, heparin cofactor II and attractin, which are involved in inflammation, lipid metabolism and vascular health. Proteins involved in lipid metabolism differed only at the symptomatic stage, whereas changes in inflammation and vascular health were evident at asymptomatic and symptomatic stages. Due to increasing evidence supporting the usefulness of ADAD as a model for LOAD, these proteins warrant further investigation into their potential association with early stages of LOAD.
引用
收藏
相关论文
共 50 条
  • [21] Modeling autosomal dominant Alzheimer's disease with machine learning
    Luckett, Patrick H.
    McCullough, Austin
    Gordon, Brian A.
    Strain, Jeremy
    Flores, Shaney
    Dincer, Aylin
    McCarthy, John
    Kuffner, Todd
    Stern, Ari
    Meeker, Karin L.
    Berman, Sarah B.
    Chhatwal, Jasmeer P.
    Cruchaga, Carlos
    Fagan, Anne M.
    Farlow, Martin R.
    Fox, Nick C.
    Jucker, Mathias
    Levin, Johannes
    Masters, Colin L.
    Mori, Hiroshi
    Noble, James M.
    Salloway, Stephen
    Schofield, Peter R.
    Brickman, Adam M.
    Brooks, William S.
    Cash, David M.
    Fulham, Michael J.
    Ghetti, Bernardino
    Jack, Clifford R., Jr.
    Voeglein, Jonathan
    Klunk, William
    Koeppe, Robert
    Oh, Hwamee
    Su, Yi
    Weiner, Michael
    Wang, Qing
    Swisher, Laura
    Marcus, Dan
    Koudelis, Deborah
    Joseph-Mathurin, Nelly
    Cash, Lisa
    Hornbeck, Russ
    Xiong, Chengjie
    Perrin, Richard J.
    Karch, Celeste M.
    Hassenstab, Jason
    McDade, Eric
    Morris, John C.
    Benzinger, Tammie L. S.
    Bateman, Randall J.
    ALZHEIMERS & DEMENTIA, 2021, 17 (06) : 1005 - 1016
  • [22] Preclinical CSF proteomic changes: a milestone in biomarker detection for autosomal dominant Alzheimer's disease
    Ross, J. Alexander
    Dodel, Richard
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2025, 10 (01)
  • [23] Discovery and validation of autosomal dominant Alzheimer's disease mutations
    Hsu, Simon
    Gordon, Brian A.
    Hornbeck, Russ
    Norton, Joanne B.
    Levitch, Denise
    Louden, Adia
    Ziegemeier, Ellen
    Laforce, Robert, Jr.
    Chhatwal, Jasmeer
    Day, Gregory S.
    McDade, Eric
    Morris, John C.
    Fagan, Anne M.
    Benzinger, Tammie L. S.
    Goate, Alison M.
    Cruchaga, Carlos
    Bateman, Randall J.
    Karch, Celeste M.
    ALZHEIMERS RESEARCH & THERAPY, 2018, 10
  • [24] ASYMPTOMATIC AUTOSOMAL DOMINANT HYPOPARATHYROIDISM IN 6 FAMILY MEMBERS OF A SYMPTOMATIC INFANT
    MARTINS, L
    BISCAIA, J
    DAMOTA, HC
    JOURNAL OF PEDIATRICS, 1985, 106 (01): : 167 - 168
  • [25] The mass spectrometry study of blood plasma proteome changes associated with Alzheimer's disease
    Fedorova, Y.
    Zakharova, N.
    Indeykina, M.
    Bugrova, A.
    Brzhozovskiy, A.
    Kolykhalov, I.
    Gavrilova, S.
    Kononikhin, A.
    Nikolaev, E.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2020, 40 : S218 - S219
  • [26] THE ALZHEIMER'S PREVENTION INITIATIVE (API) AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE (ADAD) TRIAL
    Langbaum, Jessica
    Tariot, Pierre
    Reiman, Eric
    Cho, William
    Paul, Robert
    Ward, Michael
    Romenets, Silvia Rios
    Lopera, Francisco
    NEUROBIOLOGY OF AGING, 2016, 39 : S8 - S9
  • [27] Detecting Alzheimer's disease at the pre-symptomatic stages
    Small, GW
    AGEING BRAIN: THE NEUROBIOLOGY AND NEUROPSYCHIATRY OF AGEING, 2003, : 259 - 273
  • [29] Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease
    Benzinger, Tammie L. S.
    Blazey, Tyler
    Jack, Clifford R., Jr.
    Koeppe, Robert A.
    Su, Yi
    Xiong, Chengjie
    Raichle, Marcus E.
    Snyder, Abraham Z.
    Ances, Beau M.
    Bateman, Randall J.
    Cairns, Nigel J.
    Fagan, Anne M.
    Goate, Alison
    Marcus, Daniel S.
    Aisen, Paul S.
    Christensen, Jon J.
    Ercole, Lindsay
    Hornbeck, Russ C.
    Farrar, Angela M.
    Aldea, Patricia
    Jasielec, Mateusz S.
    Owen, Christopher J.
    Xie, Xianyun
    Mayeux, Richard
    Brickman, Adam
    McDade, Eric
    Klunk, William
    Mathis, Chester A.
    Ringman, John
    Thompson, Paul M.
    Ghetti, Bernardino
    Saykin, Andrew J.
    Sperling, Reisa A.
    Johnson, Keith A.
    Salloway, Stephen
    Correia, Stephen
    Schofield, Peter R.
    Masters, Colin L.
    Rowe, Christopher
    Villemagne, Victor L.
    Martins, Ralph
    Ourselin, Sebastien
    Rossor, Martin N.
    Fox, Nick C.
    Cash, David M.
    Weiner, Michael W.
    Holtzman, David M.
    Buckles, Virginia D.
    Moulder, Krista
    Morris, John C.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (47) : E4502 - E4509
  • [30] Developing a Gene Therapy for the Treatment of Autosomal Dominant Alzheimer's Disease
    Moore, Benjamin
    Sharma, Apurwa
    Goulet, Martin
    Suter, Tracey
    Pelletier, Carolyn
    Hu, Ruoxi
    Schaeffer, Eric
    Kelleher III, Raymond J.
    HUMAN GENE THERAPY, 2023, 34 (19-20) : 1049 - 1063